{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000044","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.418397+00:00","generated_at":"2026-05-23T14:45:03.136407+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Serina presents POZ-lipid LNP data showing no immune response in rats, solving PEG antibody issue","bullets":["POZ-lipid did not trigger IgM or IgG response after repeat dosing in rats in a vaccine format.","PEG-lipid standard elicited a strong, boosted antibody response under same conditions.","Anti-PEG antibodies linked to anaphylaxis in mRNA vaccines; POZ-lipid offers immune-silent alternative.","Data presented at 4th LNP Formulation & Process Development Summit on April 15, 2025.","Discovery could enable safer LNP formulations for gene therapy and RNA medicines."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000044","json":"https://secwatch.observer/filing/0001708599-25-000044.json","markdown":"https://secwatch.observer/filing/0001708599-25-000044.md","text":"https://secwatch.observer/filing/0001708599-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000044/0001708599-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000044/ser-20250415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:45:03.136407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}